SAG
SUPN icon

SageView Advisory Group’s Supernus Pharmaceuticals SUPN Stock Holding History

SageView Advisory Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$36.6K Buy
+736
New +$35.8K ﹤0.01% 1203

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SageView Advisory Group's SUPN Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Supernus Pharmaceuticals (SUPN) in Q4 2025: 736 shares worth $36.6K. The stake represents ﹤0.01% of the portfolio and ranks #1203 among its holdings.

333 funds tracked by Wall St. Rank hold SUPN as of Q4 2025.

  • SageView Advisory Group held 736 shares of Supernus Pharmaceuticals worth $36.6K as of Q4 2025.
  • Supernus Pharmaceuticals was a new SageView Advisory Group position in Q4 2025.
  • Supernus Pharmaceuticals made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #1203 holding.
  • 333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.